Loading...
The 2021 American Society of Clinical Oncology (ASCO) meeting, held virtually June 4 to 8, showcased important and potentially practice-changing trials in gastrointestinal malignancies, as well as important updates from other recently presented trials. Here, Associate Editor David H. Ilson, MD, PhD, reviews the key trials. All meeting abstracts can be viewed in the ASCO meeting library.
Chau and colleagues presented results from CHECKMATE 648, an industry-sponsored, international, randomized, open-label, phase 3 trial that compared chemotherapy (5-fluorouracil plus cisplatin) to chemotherapy plus nivolumab and to nivolumab plus ipilimumab without chemotherapy in 970 patients with meta…